CYP19A1 and breast carcinoma: Conversely, Liu et al. observed that patients with the CYP19A1 rs4646 SNP mutation exhibited significantly longer progression-free survival (PFS) and overall survival (OS) compared to those with wild-type alleles, suggesting this mutation as a potential prognostic marker for anastrozole response in breast cancer patients.